ciprofloxacin has been researched along with Fibrosis in 8 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofloxacin (CIP) has poor lung targeting after oral inhalation." | 5.62 | Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment. ( Aldosari, BN; Alfagih, IM; Aljunaidel, HA; Almarshidy, SS; Almurshedi, AS; Alquadeib, B; Eltahir, EKD; Mohamoud, AZ, 2021) |
| " To determine if oral ciprofloxacin reduces the severity of scleroderma, a controlled, double-blind randomized clinical trial, with placebo, was conducted on 32 patients with diffuse and limited scleroderma, who received oral ciprofloxacin (250 mg) or placebo every 12 h." | 5.14 | Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma. ( Agustín, OR; Antonio, FM; Huerta, M; Iván, DE; Manuel, VR; Rubén, EC, 2010) |
| "7%), fibrosis was significantly reduced in the pentoxifylline- and ciprofloxacin-treated groups (4." | 3.70 | Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis. ( Gong, Y; Johnson, J; Kneteman, N; Minuk, GY; Moser, M; Zhang, M, 2000) |
| "A total of 150 patients with COPD, non-CF bronchiectasis or asthma, and P." | 3.11 | Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? ( Alispahic, IA; Andreassen, HF; Armbruster, K; Bangsborg, J; Bodtger, U; Browatzki, A; Christensen, CW; Coia, JE; Datcu, R; Eklöf, J; Ellingsgaard, T; Fenlev, CS; Ghathian, KSA; Gundersen, L; Harboe, ZB; Heidemann, M; Janner, J; Jensen, JUS; Jensen, TT; Johansson, SL; Johnsen, S; Kjærgaard, JL; Lapperre, TS; Linde, H; Moberg, M; Nielsen, TL; Overgaard, RH; Pedersen, L; Rosenvinge, FS; Saeed, MI; Seersholm, N; Sivapalan, P; Sørensen, VM; Titlestad, I; Ulrik, CS; Vijdea, R; Weinreich, UM; Wilcke, T; Østergaard, C, 2022) |
| "Bacterial infections are common in cirrhotic patients with acute variceal bleeding, occurring in 20% within 48 h." | 2.50 | Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. ( Lee, YY; Mahadeva, S; Tee, HP, 2014) |
| "Ciprofloxacin (CIP) has poor lung targeting after oral inhalation." | 1.62 | Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment. ( Aldosari, BN; Alfagih, IM; Aljunaidel, HA; Almarshidy, SS; Almurshedi, AS; Alquadeib, B; Eltahir, EKD; Mohamoud, AZ, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eklöf, J | 1 |
| Alispahic, IA | 1 |
| Sivapalan, P | 1 |
| Wilcke, T | 1 |
| Seersholm, N | 1 |
| Armbruster, K | 1 |
| Kjærgaard, JL | 1 |
| Saeed, MI | 1 |
| Nielsen, TL | 1 |
| Browatzki, A | 1 |
| Overgaard, RH | 1 |
| Fenlev, CS | 1 |
| Harboe, ZB | 1 |
| Andreassen, HF | 1 |
| Lapperre, TS | 1 |
| Pedersen, L | 1 |
| Johnsen, S | 1 |
| Ulrik, CS | 1 |
| Janner, J | 1 |
| Moberg, M | 1 |
| Heidemann, M | 1 |
| Weinreich, UM | 1 |
| Vijdea, R | 1 |
| Linde, H | 1 |
| Titlestad, I | 1 |
| Johansson, SL | 1 |
| Rosenvinge, FS | 1 |
| Østergaard, C | 1 |
| Ghathian, KSA | 1 |
| Gundersen, L | 1 |
| Christensen, CW | 1 |
| Bangsborg, J | 1 |
| Jensen, TT | 1 |
| Sørensen, VM | 1 |
| Ellingsgaard, T | 1 |
| Datcu, R | 1 |
| Coia, JE | 1 |
| Bodtger, U | 1 |
| Jensen, JUS | 1 |
| Almurshedi, AS | 1 |
| Aljunaidel, HA | 1 |
| Alquadeib, B | 1 |
| Aldosari, BN | 1 |
| Alfagih, IM | 1 |
| Almarshidy, SS | 1 |
| Eltahir, EKD | 1 |
| Mohamoud, AZ | 1 |
| Grimwood, K | 1 |
| Chang, AB | 1 |
| Lee, YY | 1 |
| Tee, HP | 1 |
| Mahadeva, S | 1 |
| Rubén, EC | 1 |
| Manuel, VR | 1 |
| Agustín, OR | 1 |
| Huerta, M | 1 |
| Antonio, FM | 1 |
| Iván, DE | 1 |
| Caliskan, B | 1 |
| Guven, A | 1 |
| Ozler, M | 1 |
| Cayci, T | 1 |
| Ozcan, A | 1 |
| Bedir, O | 1 |
| Surer, I | 1 |
| Korkmaz, A | 1 |
| Gomes-Filho, JE | 1 |
| Duarte, PC | 1 |
| de Oliveira, CB | 1 |
| Watanabe, S | 1 |
| Lodi, CS | 1 |
| Cintra, LT | 1 |
| Bernabé, PF | 1 |
| Moser, M | 1 |
| Zhang, M | 1 |
| Gong, Y | 1 |
| Johnson, J | 1 |
| Kneteman, N | 1 |
| Minuk, GY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter,[NCT03262142] | Phase 4 | 51 participants (Actual) | Interventional | 2018-01-10 | Terminated (stopped due to Slow recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ciprofloxacin and Fibrosis
| Article | Year |
|---|---|
Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Endoscopy; Esoph | 2014 |
2 trials available for ciprofloxacin and Fibrosis
| Article | Year |
|---|---|
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma?
Topics: Anti-Bacterial Agents; Asthma; beta-Lactams; Bronchiectasis; Ciprofloxacin; Fibrosis; Humans; Predni | 2022 |
Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma.
Topics: Administration, Oral; Adult; Ciprofloxacin; Female; Fibrosis; Humans; Kidney; Liver; Male; Middle Ag | 2010 |
5 other studies available for ciprofloxacin and Fibrosis
| Article | Year |
|---|---|
Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Chitosan; Ciprofloxacin; Drug Car | 2021 |
A new dawn: inhaled antibiotics for patients with bronchiectasis.
Topics: Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Fibrosis; Humans; Pseudomonas aeruginosa | 2019 |
Ozone therapy prevents renal inflammation and fibrosis in a rat model of acute pyelonephritis.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Aspartate Aminotransferases; Calcitonin; Ciprofloxaci | 2011 |
Tissue reaction to a triantibiotic paste used for endodontic tissue self-regeneration of nonvital immature permanent teeth.
Topics: Animals; Anti-Bacterial Agents; Apexification; Biocompatible Materials; Calcinosis; Calcium Hydroxid | 2012 |
Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis.
Topics: Animals; Anti-Infective Agents; Aspartate Aminotransferases; Bilirubin; Ciprofloxacin; Diagnosis, Co | 2000 |